Fanghänel SG, Sánchez-Reyes L, Chiquete E, De La Luz J, Escalante HA

Language: Spanish
References: 21
Page: 226-233
PDF size: 98.30 Kb.

ABSTRACT

Background: There is a lack of information on the characteristics of the medical attention delivered to Mexican patients with type 2 diabetes (T2D). Our aim was to describe the current state on the medical management of T2D in Mexico. Methods: Among 17,232 patients included in the International Diabetes Management Practices Study (IDMPS), 2,620 (15%) corresponded to Mexico. Information regarding clinical, demographics and management characteristics, as well as the impact of T2D in the patientís clinical and social condition was registered. The metabolic control and achievement of therapeutic goals were also analyzed. Results: Diagnosis of T2D was performed by the general practitioner in 76% of cases. Only about a quarter of the cohort had a blood pressure goal of ‹ 130/80 mmHg, although 97% had anti-hypertensive treatment. Management of T2D was with diet and exercise exclusively in 5%, with oral glucoselowering drugs (OGLD) in 66% (alone or combined), with OGLD and insulin in 18%, and with insulin alone in 11%. Only 31% of patients reached the goal of HbA1c ‹ 7. Self-monitoring was practiced in 50% of patients and 26% received education on diabetes. The managing physicianís personal impression about the quality of the metabolic control was not in accordance with HbA1c. Eight percent of patients had work absences in the last 3 months due to complications of T2D (mean of 15 days lost). Conclusions: In Mexico, quality of metabolic control of T2D patients could have important deficiencies. The personal impression of the physician on the patientís metabolic control is not consistent with objective data

REFERENCES

1. Villalpando S, De la Cruz V, Rojas R, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Pública Mex. 2010;52 Suppl 1:S19-26.

2. Mortalidad general. SINAIS, México, 2008. Consultada en Septiembre 20, 2010. (http://sinais.salud.gob.mx/).

3. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Pública Mex. 2010;52:S72-9.

4. Basaldúa N, Chiquete E. Common predictors of excessive adiposity in children from a region with high prevalence of overweight. Ann Nutr Metab. 2008;52:227-32.

5. Arredondo A, De Icaza E. Financial requirements for the treatment of diabetes in Latin America: implications for the health system and for patients in Mexico. Diabetología. 2009;52:1693-5.

6. Chan JC, Gagliardino JJ, Baik SH, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009;32:227-33.

7. Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract. 2009;63:997-1007.

8. López-Maldonado FJ, Reza-Albarrán AA, Suárez OJ, et al. Degree of control of cardiovascular risk factors among a patient population with diabetes mellitus type 1 and 2. Gac Med Mex. 2009;145:1-6.

9. Aguilar-Salinas C, Velázquez MO, Gómez-Pérez F, et. al. Characteristics of patients with type 2 diabetes in Mexico. Diabetes Care. 2003;26: 2021-6.

10. Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87:512-9.

11. Alba LH, Bastidas C, Vivas JM, Gil F. Prevalence of glycemic control and associated factors in type 2 diabetes mellitus patients at the Hospital Universitario de San Ignacio, Bogotá-Colombia. Gac Med Mex. 2009;145:469-74.

12. Lerman I, López-Ponce A, Villa AR, et al. Pilot study of two different strategies to reinforce self care behaviors and treatment compliance among type 2 diabetes patients from low income strata. Gac Med Mex. 2009;145:15-9.

13. Lerman I, Díaz JP, Ibarguengoitia ME, et al. Nonadherence to insulin therapy in low-income, type 2 diabetic patients. Endocr Pract. 2009; 15:41-6.

14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes source. Lancet. 1998;352:837-53.

15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes source. Lancet. 1998;352:854-65.

16. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21-9.

17. Buse JB, Bigger JT, Byington RP, et al., from ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i-33.

18. Gerstein HC, Miller ME, Byington RP, et al., from Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.

19. Patel A, MacMahon S, Chalmers J, et al., from ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.

20. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.

21. Coronado-Malagón M, Gómez-Vargas JI, Espinoza-Peralta D, Arce-Salinas A. Progression toward type-2 diabetes mellitus among Mexican prediabetics. Assessment of a cohort. Gac Med Mex. 2009;145:269-72.